Compare Rivian Automotive, Inc. (RIVN) vs TG Therapeutics Inc (TGTX) Price & Performance

Rivian Automotive (RIVN) trades at $14.33, down slightly by 0.07% on the day, amid a bearish technical outlook but with improving operational trends. The company reported record Q3 2026 deliveries of 19,248 vehicles, beating estimates and reaffirming full-year guidance, though the stock dipped as investors hoped for a forecast upgrade. Financially, revenue growth continues but losses persist, with a net income margin of -54.95% in 2025, while cash burn has moderated from prior years.

The outlook remains challenged by high cash burn and competitive pressures, but cost controls and R2 SUV ramp-up offer a path to profitability. Analyst consensus is cautiously optimistic with a $16.89 price target, though risks include execution delays and EV market volatility. The stock presents a high-risk, high-reward opportunity for investors betting on Rivian's scaling and autonomy initiatives.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.